Statin utilization and low-density lipoprotein cholesterol in statin-treated patients with atherosclerotic cardiovascular disease: Trends from a community-based health care delivery system, 2002–2016

Lipid goal attainment in post‐acute coronary syndrome patients in China: Results from the 6‐month real‐world dyslipidemia international study II

“…The patient and physician related factors for lower LDL-C goal attainment in a community based study in the US and CEPHEUS II study for secondary prevention were suboptimal adherence, a lower rate of high-intensity statin prescriptions, dissatisfaction with the treatment, physicians not setting the lipid goals, and guideline nonconcordance. 33,34 In our study, 88.9% from the LLT group and 81.9% from the non-LLT group completed 6-month follow-up, with lost to follow-up and withdrawal being the common reasons for discontinuing the study. In all, 20 deaths were also reported.…”

Lipid-Lowering Therapy Use and Intensification Among United States Veterans Following Myocardial Infarction or Coronary Revascularization Between 2015 and 2019

“…Therapeutic inertia, the act of not intensifying a medication regimen despite having a medical indication, has been identified as a barrier to statin and PCSK9i use. [24][25][26] Lipid testing and outpatient follow-up visits after an MI or coronary revascularization are important in reducing Two columns (left-to-right): (1) veterans taking no LLT or a low-moderate intensity statin only before hospitalization for MI or elective coronary revascularization who were intensified within 3 mo following hospital discharge, (2) veterans taking a high-intensity statin only, ezetimibe only, or any statin and ezetimibe before hospitalization for MI or elective coronary revascularization who were intensified within 3 mo following hospital discharge. Prevalence ratio (PR) was obtained from modified Poisson regression with robust error variance.…”

Bempedoic Acid for Lipid Management in the Indian Population: An Expert Opinion

“…In assessing the prescribing of HIS after ASCVD, Romanelli et al reported that HIS was initiated only in 16.6%. The rate of intensification of statin therapy over the mean follow-up period of 16.8 months was 8.4 per 100 person-years [ 30 ]. The DA VINCI study from the European Union observed that among patients in the very high-risk primary and secondary prevention groups, HIS monotherapy was used in 20% and 38%, respectively [ 31 ].…”

“…In the DA VINCI study, LDL-C goal attainment rates as per 2019 ESC/EAS guidelines among very-high-risk primary and secondary prevention patients were 17% and 22%, respectively. The combined use of ezetimibe or any LLT with PCSK9 inhibitor was associated with 2019 goal attainment rates of 20% and 58%, respectively [ 30 ]. In a study of a cohort of CAD patients from Sweden, Mazhar et al [ 36 ] observed that despite an increase in the proportion of patients receiving HIS from 12% in 2012 to 78% in 2018 and remaining adherent (over 80% adherence), the LDL-C goal attainment rates remained at 52% at one year and <50% in subsequent years.…”